Brent Davis

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

Sensyne Health Holdings Ltd. provides wireless charging technology. It focuses on developing wireless energy devices and wireless sensor networks. The company was founded by Elspeth Drayson, Paul R. Drayson and Manuel Pinuela in April 2014 and is headquartered in London, the United Kingodm.

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom.

Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK.

Circassia Ltd. develops medicines for allergic and auto-immune diseases. The company was founded by Anthony Barrington Kay and Mark Larché on December 29, 1998 and is headquartered in Oxford, the United Kingdom.

Pleco Therapeutics BV is a Dutch clinical stage specialty pharmaceutical company that aims to improve the effectiveness of existing chemotherapy through its novel plecoid™ therapies. The company is based in Nijmegen, Netherlands. These therapies have the potential to positively change the balance of protein expression within the cancer microenvironment, removing the burden of toxic metals within the cell. The CEO of the company is Ivo Timmermans.

University of Birmingham Enterprise Ltd (University of Birmingham Enterprise) is a venture capital subsidiary of University of Birmingham founded in 2008. The firm is headquartered in Birmingham, United Kingdom.

The Institute of Directors (United Kingdom) is a community of passionate UK business leaders. The non-profit company is based in Birmingham, UK, and has subsidiaries in the United Kingdom. The British company provides professional training opportunities and access to essential help and resources for its members. The CEO of the company is Stephen Martin.

Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom.

DC Biosciences Ltd. provides bioreagents and life science services. The firm’s products include cell extracts, fresh primary mammalian cells, recombinant proteins, steroid beads, fluorescent cell markers, and SILAC reagents. Its services include custom antibody service, custom antibody service, DNA cloning services, gene synthesis service, and protein expression, gene to stable cell line, mass spectrometry, quantitative proteomics, and peptide synthesis. The company was founded by Angus Lamond and Paul Ajuh in June 2006 and is headquartered in Dundee, the United Kingdom.

Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom.

Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom.

iQur Ltd. develops vaccines based on tandem core vaccine technology. The firm offers fibrosis assessment in viral hepatitis and other chronic liver diseases, and developing new treatments for serious liver disease through drug discovery research programs. The company was founded by William Rosenberg on February 13, 2003 and is headquartered in London, the United Kingdom.